This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2023 Med Learning Group. Built by Divigner. All Rights Reserved.
Reading and Resources
The following list includes websites and articles with comprehensive information about melanoma.
Treatment Guidelines
| Guidelines | Link to guidelines |
|---|---|
| NCCN Clinical Practice Guidelines. (V1.2023) | https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf |
| ESMO Clinical Practice Guidelines. (2019) | https://www.esmo.org/guidelines/guidelines-by-topic/melanoma/cutaneous-melanoma |
Glossary of FDA approved drugs for Advanced Melanoma
| Generic name | Trade name | Link to prescribing information |
|---|---|---|
| Atezolizumab | Tecentriq® | https://www.tecentriq.com/melanoma.html |
| Binimetinib | Mektovi® | https://www.braftovimektovi.com/ |
| Cobimetinib | Cotellic® | https://www.cotellic.com/ |
| Dabrafenib | Tafinlar® | https://www.us.tafinlarmekinist.com/ |
| Encorafenib | Braftovi® | https://www.braftovimektovi.com/ |
| Entrectinib* | RozlytrekTM | https://www.rozlytrek.com/ |
| Interleukin-2 | Proleukin® (Aldesleukin) | https://proleukin.com/ |
| Ipilimumab | Yervoy® | https://www.yervoy.com/ |
| Larotectinib* | Vitrakvi® | https://hcp.vitrakvi-us.com/ |
| Nivolumab | Opdivo® | https://www.opdivo.com/ |
| Nivolumab plus Relatlimab | OpdualagTM | https://www.opdualag.com/ |
| Pembrolizumab | Keytruda® | https://www.keytruda.com/melanoma/ |
| Talimogene laherparepvec | Imlygic® | https://www.imlygic.com/ |
| Trametinib | Mekinist® | https://www.us.tafinlarmekinist.com/ |
| Vemurafenib | Zelboraf® | https://www.gene.com/patients/medicines/zelboraf |
Ongoing clinical trials and new therapeutics for advanced cutaneous melanoma1
| Agent | Phase | Study |
|---|---|---|
| Atezolizumab + Bevacizumab | 2 | NCT04356729 |
| Atezolizumab + Cobimetinib + Vemurafenib | 3 | NCT02908672 |
| Botensilimab | 2 | NCT05529316 |
| Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab -or- Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib | 3 | NCT02224781 |
| Dabrafenib and/or Trametinib Rollover study | 4 | NCT03340506 |
| Encorafenib + Binimetinib | 3 | NCT05270044 |
| Encorafenib + Binimetinib + Pembrolizumab | 3 | NCT04657991 |
| Fianlimab + Cemiplimab | 3 3 | NCT05352672 NCT05608291 |
| Imiquimod + Pembrolizumab | 1 | NCT03276832 |
| Ipilimumab | 4 | NCT02068196 |
| Ipilimumab + Imatinib mesylate | 1 | NCT01738139 |
| Nivolumab + Ipilimumab | 3 3 3 3 3 | NCT04949113 NCT03068455 NCT02388906 NCT01844505 NCT02599402 |
| Nivolumab + Ipilimumab + GM-CSF | 2/3 | NCT02339571 |
| Nivolumab/CMP-001 + Nivolumab | 2/3 | NCT04695977 |
| Nivolumab/HBI-8000 + Nivolumab | 3 | NCT04674683 |
| Nivolumab + Relatlimab | 3 3 2/3 | NCT05002569 NCT05625399 NCT03470922 |
| Panobinostat + Ipilimumab | 1 | NCT02032810 |
| PDR001 + Dabrafenib + Trametinib | 3 | NCT02967692 |
| Pembrolizumab + Infliximab | 2 | NCT05034536 |
| Pembrolizumab + Lenvatinib | 3 | NCT03820986 |
| Pembrolizumab/IO102-IO103 + Pembrolizumab | 3 | NCT05155254 |
| PeptiCRAd-1 + Pembrolizumab | 1 | NCT05492682 |
| Talimogene laherparepvec (T-VEC) + Nivolumab | 2 | NCT04330430 |
| Talimogene laherparepvec (T-VEC) + Pembrolizumab | 2 | NCT02965716 |
| Tebentafusp/Tebentafusp + Pembrolizumab | 2/3 | NCT05549297 |
| Tislelizumab + Dacarbazine | 2 | NCT05466474 |
Websites
| Resource | Address |
|---|---|
| AIM at Melanoma Foundation | https://www.aimatmelanoma.org/ |
| American Cancer Society (ACS). Melanoma Skin Cancer | https://www.cancer.org/cancer/melanoma-skin-cancer.html |
| ASCO Cancer.Net. Melanoma | https://www.cancer.net/cancer-types/melanoma |
| Cancer Support Community | https://www.cancersupportcommunity.org/ |
| Caregiver Action Network | https://www.caregiveraction.org/ |
| Mayo Clinic. Melanoma | https://www.mayoclinic.org/diseases-conditions/melanoma/symptoms-causes/syc-20374884 |
| MedlinePlus. Melanoma | https://medlineplus.gov/melanoma.html |
| Melanoma Research Foundation | https://melanoma.org/ |
| National Cancer Institute. Melanoma Treatment (PDQ®) – Health Professional Version | https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq |
| National Cancer Institute. New therapies are changing the outlook for advanced melanoma | https://www.cancer.gov/types/skin/research/advanced-melanoma-therapies |
| National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 1.2023 | https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf |
| US National Library of Medicine. Clinical Trials | https://clinicaltrials.gov/ |
References
- US National Library of Medicine. Clinical Trials. https://clinicaltrials.gov/ct2/home
